

RAISBECK, LARA, RODRÍGUEZ & RUEDA
MIEMBROS DE LA FIRMA
BAKER & MCKENZIE

CALLE 35 No. 7-25, Piso 4
TELÉFONO: (57-1) 332-2600
BOGOTÁ, D.C. COLOMBIA
WWW.BAKERINFO.COM
OFFICE.BOGOTA@BAKERNET.CO

2
SUPERINDUSTRIA Y COMERCIO
Radicación: 00063457 00000001 Folios: 84
Fecha (AMD): 2000-11-10 16:48:42
Trámite: 002 PATENTES D 1 REGISTRO/ 329 COMPLEMEN
Dependencia: 2020 DIVISION DE NUEVAS CREACIONES

Señores

SUPERINTENDENCIA DE INDUSTRIA Y COMERCIO
DIVISION DE NUEVAS CREACIONES

E. _____ S. _____ D. _____


Re: **Expediente No. 00.063.457**

Solicitud de Patente de Invención titulada: "LAS
RUTAS SINTETICAS EFICIENTES PARA LA
PREPARACION DE LOS INHIBIDORES DE LA
PROTEASA DEL RINOVIRUS Y LOS
INTERMEDIOS CLAVES".

Solicitante: **AGOURON PHARMACEUTICALS, INC.**

CARLOS R. OLARTE, mayor de edad y vecino de Bogotá, identificado tal como aparece al pie de mi firma en mi carácter de apoderado de la sociedad solicitante, respetuosamente presento junto con este escrito la Copia Certificada de la Solicitud de Patente No. 60/150.358, de la cual se reivindica prioridad en la presente solicitud, así como la traducción de su Capítulo Reivindicatorio.

Atentamente,



CARLOS R. OLARTE
C.C. No. 79.782.747 de Bogotá
T.P. 74.295

Anexos: Copia Certificada del Documento de Prioridad
Traducción del Capítulos Reivindicatorio del Documentos de Prioridad.

88
A

LOS ESTADOS UNIDOS DE AMERICA

A TODOS AQUELLOS A QUIEN SE LES PRESENTE ESTE DOCUMENTO

DEPARTAMENTO DE COMERCIO DE LOS ESTADOS UNIDOS

Oficina de Patentes y Marcas de los Estados Unidos

8 de septiembre de 2000

ESTO ES PARA CERTIFICAR QUE LO ANEXADO AQUI ES UNA COPIA
VERDADERA DE LOS REGISTROS DE LA OFICINA DE PATENTES Y
MARCAS DE LOS ESTADOS UNIDOS DE AQUELLOS PAPELES DE ESTA
SOLICITUD IDENTIFICADA ENSEGUIDA QUE CUMPLIÓ CON LOS
REQUISITOS PARA SER OTORGADA UNA FECHA DE PRESENTACIÓN BAJO
35 USC 111.

NUMERO DE SOLICITUD: 60/150,358

FECHA DE RADICACION: 24 de agosto de 1999

Por autoridad de

El COMISIONADO DE PATENTES Y

MARCAS

Sello de la Oficina de
Patentes y Marcas de
los Estados Unidos
de América

(Firmado H. L. Jackson)

H. L. Jackson



Oficial de

Certificación


SE AFIRMA LO SIGUIENTE:

1. Un proceso útil en la sintetización de compuestos contra el picornavirus, que consta de:


- (a) realizar la cianometilación de un compuesto de la fórmula V utilizando bis(trimetisilo)amida y bromoacetonitrilo para producir un compuesto de la fórmula VI;



- (b) realizar la disminución, luego la ciclización, y después la desprotección del compuesto de la fórmula VI para producir un compuesto de la fórmula VII; y



(c) realizar la oxidación y olefinación del compuesto de la fórmula VII mediante la reacción del compuesto de la fórmula VII con un complejo de SO₃-piridina para producir una mezcla de reacción y reaccionar la mezcla de reacción con un compuesto para la fórmula VIII para formar un compuesto de la fórmula IV:



5

en donde R₁ es H, F, un grupo alquilo, OH, SH, o un grupo O-alquilo;

donde cada R₄₁ es independientemente H o un alquilo inferior; y X es cualquier grupo protector aceptado para nitrógeno.


2. El proceso de la afirmación 1, en donde el compuesto de la fórmula V es preparado
- 10 a partir de N-Boc L ácido glutámico γ-benzilo éster.
3. El proceso de la afirmación 1, en donde X es un grupo Boc.
4. El proceso de la afirmación 1, en donde R₄₁ es H.
5. El proceso de la afirmación 1, en donde Z₁ es H.
6. El proceso de la afirmación 1, en donde Z es -COOEt.
- 15 7. Un proceso útil en la sintetización contra el picornavirus de los compuestos de acuerdo a la afirmación 1, que además consta de los siguientes pasos:

(d) desproteger el compuesto de la fórmula IV para el rendimiento de un compuesto de la fórmula IVA:

20


94 91

7




; y

- (e) someter un compuesto de la fórmula II y el compuesto de la fórmula IVA a una
- 5 reacción para la formación de amida, para producir un compuesto de la fórmula IA:




en donde R_2 y R_3 son cada uno independientemente H;




- 10 donde n es un número entero del 0 al 5, A_1 es CH o N, A_2 y cada A_3 son independientemente seleccionados de $C(R_{41})(R_{41})$, $N(R_{41})$, S, $S(O)$, $S(O)_2$, y O, y A_4 es NH o NR_{41} , donde cada R_{41} es independientemente H o un alquilo inferior, siempre

que no mas de dos heteroátomos ocurran consecutivamente en el anillo ilustrado arriba
 formado por A₁, A₂, (A₃)_n, A₄ y C=O, y por lo menos uno de los R₂ y R₃ es



R₄ es



5


R₅ y R₆ son cada uno independientemente H, F, un grupo alquilo, un grupo
 cicloalquilo, un grupo heterocicloalquilo, un grupo arilo, y un grupo heteroarilo;
 R₇ y R₈ son cada uno independientemente H, un grupo alquilo, un grupo cicloalquilo,
 un grupo heterocicloalquilo, un grupo arilo, un grupo heteroarilo , -OR₁₇, -SR₁₇, -
 10 NR₁₇R₁₈, -NR₁₉NR₁₇R₁₈, o -NR₁₇OR₁₈, donde R₁₇, R₁₈, y R₁₉ son cada uno
 independientemente H, un grupo alquilo, un grupo cicloalquilo , un grupo
 heterocicloalquilo , un grupo arilo, un grupo heteroarilo, o un grupo acilo, siempre que
 por lo menos uno de los R₇ y R₈ sea un grupo alquilo, un grupo arilo, un grupo
 heteroarilo, -OR₁₇, -SR₁₇, -NR₁₇R₁₈, -NR₁₉NR₁₇R₁₈, o -NR₁₇OR₁₈;

15

R₉ es un heterociclo de cinco miembros compuesto de uno a tres heteroátomos
 seleccionados de O, N, y S; y


Z y Z₁ son cada uno independientemente H, F, un grupo alquilo, un grupo cicloalquilo,
 un grupo heterocicloalquilo, un grupo arilo, un grupo heteroarilo, -C(O)R₂₁, -CO₂R₂₁, -
 CN, -C(O)NR₂₁R₂₂, -C(O)NR₂₁OR₂₂, -C(S)R₂₁, -C(S)NR₂₁R₂₂, -NO₂, -SOR₂₁, -SO₂R₂₁,

- SO₂NR₂₁R₂₂, -SO(NR₂₁)(OR₂₂), -SONR₂₁, -SO₃R₂₁, -PO(OR₂₁)₂, -PO(R₂₁)(R₂₂),
 -PO(NR₂₁R₂₂)(OR₂₃), -PO(NR₂₁R₂₂)(NR₂₃R₂₄), -C(O)NR₂₁NR₂₂R₂₃, o
 -C(S)NR₂₁NR₂₂R₂₃, donde R₂₁, R₂₂, R₂₃, y R₂₄ son cada uno independientemente H, un
 grupo alquilo, un grupo cicloalquilo, un grupo heterocicloalquilo, un grupo arilo, un
 grupo heteroarilo, un grupo acilo, o un grupo tioacilo, o donde cada dos de los R₂₁,
 5 R₂₂, R₂₃, y R₂₄, junto con los átomos a los cuales están enlazados, forman un grupo
 heterocicloalquilo, siempre que Z y Z₁ no sean ambos H;
 o Z₁ y R₁, junto con los átomos a los cuales están enlazados, forman un grupo
 cicloalquilo o heterocicloalquilo, donde Z₁ y R₁ son tal como se definen arriba a
 10 excepción de las fracciones que no pueden formar el grupo cicloalquilo o
 heterocicloalquilo;
 o Z y Z₁, junto con los átomos a los cuales están enlazados, forman un grupo
 cicloalquilo o heterocicloalquilo, donde Z y Z₁ son tal como se definen arriba a
 excepción de las fracciones que no pueden formar el grupo cicloalquilo o
 15 heterocicloalquilo.
8. El proceso de la afirmación 7, en donde X es un grupo Boc.
9. El proceso de la afirmación 7, en donde el compuesto IV es




10. El proceso de la afirmación 7, en donde el compuesto de la fórmula II es


97 94



11. El proceso de la afirmación 7, en donde el compuesto de la fórmula IVA es




12. El proceso de acuerdo a la afirmación 7, en donde el compuesto de la fórmula IA es




5

13. Un proceso útil en la sintetización de compuestos contra el picornavirus, que consta de:

- (a) efectuar la alquilación dianónica de un compuesto de la fórmula IX
- utilizando bromoacetnitrilo para preparar un compuesto de la fórmula X;




(IX)




(X)

(b) efectuar la hidrogenación del compuesto de la fórmula para producir una amina de la fórmula XI;




5

(c) reaccionar el compuesto de la fórmula XI con ET_3N para producir un éster de lactama de la fórmula XII;





(d) efectuar la reducción del éster de lactama de la fórmula XII para producir un compuesto de la fórmula XIII:



10

(e) efectuar la oxidación y olefinación del compuesto de la fórmula XIII para producir un compuesto de la fórmula XIV al reaccionarlo con un compuesto de la fórmula XV:





en donde cada R_{41} es independientemente H o un alquilo inferior;

Z y Z_1 son cada uno independientemente H, F, un grupo alquilo, un grupo cicloalquilo, un grupo heterocicloalquilo, un grupo arilo, un grupo heteroarilo, $-C(O)R_{21}$, $-CO_2R_{21}$, -

5 CN , $-C(O)NR_{21}R_{22}$, $-C(O)NR_{21}OR_{22}$, $-C(S)R_{21}$, $-C(S)NR_{21}R_{22}$, $-NO_2$, $-SOR_{21}$, $-SO_2R_{21}$, $-SO_2NR_{21}R_{22}$, $-SO(NR_{21})(OR_{22})$, $-SONR_{21}$, $-SO_3R_{21}$, $-PO(OR_{21})_2$, $-PO(R_{21})(R_{22})$, $-PO(NR_{21}R_{22})(OR_{23})$, $-PO(NR_{21}R_{22})(NR_{23}R_{24})$, $-C(O)NR_{21}NR_{22}R_{23}$, o

$-C(S)NR_{21}NR_{22}R_{23}$, donde R_{21} , R_{22} , R_{23} , y R_{24} son cada uno independientemente H, un grupo alquilo, un grupo cicloalquilo, un grupo heterocicloalquilo, un grupo arilo, un

10 grupo heteroarilo, un grupo acilo, o un grupo tioacilo, o donde cada dos de los R_{21} , R_{22} , R_{23} , y R_{24} , junto con los átomos a los cuales están enlazados, forman un grupo heterocicloalquilo, siempre que Z y Z_1 no sean ambos H;


o Z y Z_1 , junto con los átomos a los cuales están enlazados, forman un grupo cicloalquilo o heterocicloalquilo, donde Z y Z_1 son tal como se definen arriba a

15 excepción de las fracciones que no pueden formar el grupo cicloalquilo o heterocicloalquilo; y

X es cualquier grupo protectivo adecuado para nitrógeno.

14. El proceso útil en la sintetización de compuestos contra el picornavirus de acuerdo a la afirmación 13, además consta de:

preparar un compuesto de la fórmula IV al convertir el compuesto de la fórmula XIV para producir un compuesto de la fórmula IV:




en donde R₁ es H, F, un grupo alquilo, OH, SH, o un grupo O-alquilo.

15. El proceso útil en la sintetización de compuestos contra el picornavirus de acuerdo



5 a la afirmación 14, además consta de:

Paso A: desproteger el compuesto de la fórmula IV para producir un compuesto de la fórmula IVA:




Paso B: someter un compuesto de la fórmula II y el compuesto de la fórmula

10 IVA a una reacción amida formante para producir un compuesto de la fórmula IA:




en donde R_2 y R_3 son cada uno independientemente H;




donde n es un número entero del 0 al 5, A_1 es CH o N, A_2 y cada A_3 son

independientemente seleccionados de $C(R_{41})(R_{41})$, $N(R_{41})$, S, $S(O)$, $S(O)_2$, y O, y A_4 es

- 5 NH o NR_{41} , donde cada R_{41} es independientemente H o un alquilo inferior, siempre que no mas de dos heteroátomos ocurran consecutivamente en el anillo ilustrado arriba formado por A_1 , A_2 , $(A_3)_n$, A_4 y $C=O$, y por lo menos uno de los R_2 y R_3 es



R_4 es



R_5 y R_6 son cada uno independientemente H, F, un grupo alquilo, un grupo

- 10 cicloalquilo, un grupo heterocicloalquilo, un grupo arilo, o un grupo heteroarilo;

R_7 y R_8 son cada uno independientemente H, un grupo alquilo, un grupo cicloalquilo,

un grupo heterocicloalquilo, un grupo arilo, un grupo heteroarilo, $-OR_{17}$, $-SR_{17}$, -

$NR_{17}R_{18}$, $-NR_{19}NR_{17}R_{18}$, o $-NR_{17}OR_{18}$, donde R_{17} , R_{18} , y R_{19} son cada uno


independientemente H, un grupo alquilo, un grupo cicloalquilo, un grupo

- 15 heterocicloalquilo, un grupo arilo, un grupo heteroarilo, o un grupo acilo, siempre que

- por lo menos uno de los R_7 y R_8 sean un grupo alquilo, un grupo arilo, un grupo heteroarilo, $-OR_{17}$, $-SR_{17}$, $-NR_{17}R_{18}$, $-NR_{19}NR_{17}R_{18}$, o $-NR_{17}OR_{18}$;
- R_9 es un heterociclo de cinco miembros el cual tiene de uno a tres heteroátomos seleccionados de O, N, y S;
- 5 Z y Z_1 son cada uno independientemente H, F, un grupo alquilo, un grupo cicloalquilo, un grupo heterocicloalquilo, un grupo arilo, un grupo heteroarilo, $-C(O)R_{21}$, $-CO_2R_{21}$, $-CN$, $-C(O)NR_{21}R_{22}$, $-C(O)NR_{21}OR_{22}$, $-C(S)R_{21}$, $-C(S)NR_{21}R_{22}$, $-NO_2$, $-SOR_{21}$, $-SO_2R_{21}$, $-SO_2NR_{21}R_{22}$, $-SO(NR_{21})(OR_{22})$, $-SONR_{21}$, $-SO_3R_{21}$, $-PO(\overline{OR_{21}})_2$, $-PO(R_{21})(R_{22})$, $-PO(NR_{21}R_{22})(OR_{23})$, $-PO(NR_{21}R_{22})(NR_{23}R_{24})$, $-C(O)NR_{21}NR_{22}R_{23}$, o
- 10 $-C(S)NR_{21}NR_{22}R_{23}$, donde R_{21} , R_{22} , R_{23} , y R_{24} son cada uno independientemente H, un grupo alquilo, un grupo cicloalquilo, un grupo heterocicloalquilo, un grupo arilo, un grupo heteroarilo, un grupo acilo, o un grupo tioacilo, o donde cualquiera de dos de los R_{21} , R_{22} , R_{23} , y R_{24} , junto con los átomos a los cuales están enlazados forman un grupo heterocicloalquilo, siempre que Z y Z_1 no sean ambos H;
- 15 o Z_1 y R_1 , junto con los átomos a los cuales están enlazados, forman un grupo cicloalquilo o heterocicloalquilo, donde Z_1 y R_1 son tal como se definen arriba a excepción de las fracciones que no pueden formar el grupo cicloalquilo o heterocicloalquilo;
- o Z y Z_1 , junto con los átomos a los cuales están enlazados, forman un grupo
- 20 cicloalquilo o heterocicloalquilo, donde Z y Z_1 son tal como se definen arriba a excepción de que no pueden formar el grupo cicloalquilo o heterocicloalquilo.
15. El proceso de la afirmación 13, en donde X es un grupo Boc.
16. El proceso de la afirmación 13, en donde R_{41} es H.
17. El proceso de la afirmación 13, en donde Z_1 es H.

#


18. El proceso de la afirmación 13, en donde Z es $-\text{COOEt}$.
19. El proceso de la afirmación 14, en donde R_1 es H.
20. Un proceso útil para la síntesis del compuesto de la fórmula A IA', y por lo tanto de las sales de adición ácidas:



5

consta de los siguientes pasos:


Paso A: la preparación de un compuesto de la fórmula IV':



que consta de:

- (a) efectuar la cianometilación de un compuesto de la fórmula V' utilizando bis(trimetisilo)amida y bromoacetonitrilo para producir un compuesto de la fórmula VI';

10





~~104~~

107

#

(b) efectuar la reducción, la ciclización, y después la desprotección del compuesto de la fórmula VI' para producir un compuesto de la fórmula VII'; y




5


(c) efectuar la oxidación y olefinación del compuesto de la fórmula VII a través de la reacción del compuesto con un complejo de SO₃-piridina antes de que la mezcla de reacción resultante sea reaccionada con Ph₃P=CHCO₂Et;

106
107
#

Paso B: desproteger el compuesto de la fórmula IV para producir un compuesto de la fórmula IVA':





5 Paso C: someter un compuesto de la fórmula II' y el compuesto de la fórmula IVA' a una reacción para la formación de amida;




21. El proceso de la afirmación 20, en donde el compuesto de la fórmula V es preparado a partir de N-Boc L ácido glutámico γ -benzilo éster.
22. Un proceso útil en la sintetización de compuestos contra el picornavirus, que
- 10 consta de:
- (a) efectuar la alquilación dianónica de un compuesto de la fórmula IX' utilizando bromoacetonitrilo para preparar un compuesto de la fórmula X';


103 + 106



(b) efectuar la hidrogenación del compuesto de la fórmula X' para producir una amina de la fórmula XI';




5 (c) reaccionar el compuesto de la fórmula XI' con ET_3N para producir un éster de lactama de la fórmula XII';




(d) efectuar la reducción del éster de lactama de la fórmula XII' para producir un compuesto de la fórmula XIII':

104/07




(e) efectuar la oxidación y olefinación del compuesto de la fórmula XIII' para producir un compuesto de la XIV' a través de la reacción con $\text{Ph}_3\text{P}=\text{CHCO}_2\text{Et}$;



- 5 23. El proceso útil en la sintetización de compuestos contra el picornavirus de acuerdo a la afirmación 22, además consta de:
- convertir el compuesto de la fórmula XIV' al compuesto de la fórmula IV';


10



105-100

24. El proceso útil en la sintetización de compuestos contra el picornavirus de acuerdo a la afirmación 23, además consta de:


Paso A: la desprotección del compuesto de la fórmula IV' para producir un compuesto de la fórmula IVA':



5


; y

Paso C: someter un compuesto de la fórmula II' y el compuesto de la fórmula IVA' a una reacción para la formación de amida;



10

109
106
7



THE UNITED STATES OF AMERICA

TO ALL TO WHOM THESE PRESENTS SHALL COME:

UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

September 08, 2000

THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A FILING DATE UNDER 35 USC 111.

APPLICATION NUMBER: 60/150,358

FILING DATE: August 24, 1999



**By Authority of the
COMMISSIONER OF PATENTS AND TRADEMARKS**

H. L. Jackson

H. L. JACKSON

Certifying Officer

Attorney's Docket No.: 0125-0028

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Q. Tian et al.

For: Efficient Synthetic Routes For the
Preparation Of Rhinovirus Protease Inhibitors And Key Intermediates

Box Provisional Patent Application
Assistant Commissioner for Patents
Washington, DC 20231

COVER SHEET FOR FILING PROVISIONAL APPLICATION
(37 C.F.R. § 1.51(2)(i))

This is a request for filing a PROVISIONAL APPLICATION FOR PATENT under
37 C.F.R. 1.53(b)(2).

The following comprises the information required by 37 C.F.R. § 1.51(a)(2)(i).

1. The name(s) and address(es) of the inventor(s) is/are (37 C.F.R. § 1.51(a)(2)(i)(B)
and 37 C.F.R. § 1.51(a)(2)(i)(C)):

Qingping Tian: 7665 Palmilla Dr., #5110, San Diego, CA 92122;
Naresh K. Nayyar: 5340 Toscana Way #F-112, San Diego, CA 92122;
Srinivasan Babu: 10914 Jasmine Crest Lane, San Diego, CA 92121;
Junhua Tao: 8945 Lombard Place, Apt. 520, San Diego, CA 92121
Terence Jarold Moran: 11947 Dapple Way, San Diego CA 92128;
Raymond Dagnino, Jr.: 11365 Surco Drive, San Diego, CA 92126;
Travis P. Remarchuk: 5204 Palo Verde Road, Irvine, CA 92612;
Michael J. Melnick: 6705 Forum Street, San Diego, CA 92111;
Lennert J. Mitchell, Jr.: 3823 Paris Street, Hemet, CA 92545;
Steven L. Bender: 915 Resse Steet, Oceanside, CA 92054;

2. The title of the invention is (37 C.F.R. § 1.51(a)(2)(i)(D)):
Efficient Synthetic Routes For The Preparation Of Rhinovirus Protease Inhibitors
And Key Intermediates

3. The name, registration, and telephone number of the attorney (if applicable) is (37
C.F.R. § 1.51(a)(2)(i)(E)):

Name of attorney: Simon D. Roberts

Reg. No.: Certificate of Limited
Recognition Under 37CFR § 10.9(b)

Tel. (703) 683-3600

(complete the following, if applicable)

☐ A power of attorney accompanies this cover sheet.

108
7

4. The docket number used to identify this application is (37 C.F.R. § 1.51(a)(2)(i)(F)):

Docket No.: 0125-0028

5. The correspondence address for this application is (37 C.F.R. § 1.51(a)(2)(i)(G)):

Shanks & Herbert
TransPotomac Plaza
1033 N. Fairfax Street, Suite 306
Alexandria, VA 22314

6. Statement as to whether invention was made by an agency of the U.S. Government or under contract with an agency of the U.S. Government. (37 C.F.R. § 1.51(a)(2)(i)(H)):

This invention was made by an agency of the United States Government, or under contract with an agency of the United States Government.

- ☒ No.
☐ Yes.

The name of the U.S. Government agency and the Government contract number are: _____

7. Identification of documents accompanying this cover sheet:

- A. Documents required by 37 C.F.R. §§ (a)(2)(ii)-(iii):

Specification:
Drawings:

No. of pages 43
No. of sheets 0

- B. Additional documents:

- ☒ Claims
☐ Power of attorney
☐ Small entity statement
☐ Assignment
☐ Other

No. of claims 24

8. Fee

The filing fee for this provisional application, as set in 37 C.F.R. § 1.16(k), is \$150.00, for other than a small entity, and \$75.00, for a small entity.

- ☐ Applicant is a small entity.

5-10-2009 10:00:00

#2
109
7

9. ☒ Fee payment is being made at this time.

☐ Not enclosed

☐ No filing fee is to be paid at this time. (This and the surcharge required by 37 C.F.R. § 1.16(l) can be paid subsequently.)

☒ Enclosed

Total fee enclosed \$ 150.00


10. Method of fee payment

☒ Check in the amount of \$150.00

☐ Charge Account No. _____, in the amount of \$
A duplicate of this Cover Sheet is attached.

Please charge Account No. 500622 for any fee deficiency.

Date: *August 29, 1999*



Signature of attorney

Reg. No.: Cert. of Limited Recognition
Tel.: (703) 683-3600

60150350 082499

H3
110
28

0125.0028

**Efficient Synthetic Routes
For The Preparation Of
Rhinovirus Protease Inhibitors
And Key Intermediates**

00150351 082499

INVENTORS:

Q. Tian, N. Nayyar, S. Babu, J. Tao, T. Moran, R. Dagnino, Jr., T. Remarchuk, M. Melnick, L. Mitchell, Jr., and S. Bender.

HA
111
2

TITLE:

Efficient Synthetic Routes For The Preparation Of Rhinovirus Protease Inhibitors And Key Intermediates

RELATED APPLICATION DATA:

This application relates to a concurrently filed Provisional Patent Application No. _____ (Attorney Docket No. 0125.0027) entitled "Efficient Methods For The Preparation Of Rhinovirus Protease Inhibitors, Key Intermediates And A Continuous Membrane Reactor Useful For The Preparation Of The Same" having named as inventors: J. Tao, S. Babu, R. Dagnino, Jr., Q. Tian, T. Remarchuk, K. McGee, N. Nayyar, and T. Moran. The aforementioned application also relates to synthetic routes for the preparation of rhinovirus protease inhibitors, as well as key intermediates useful in their preparation. This concurrently filed application is entirely incorporated herein by reference.

TECHNICAL FIELD AND INDUSTRIAL APPLICABILITY OF INVENTION:

The present invention relates to an improved process for the preparation of ethyl-3-((5'-methylisoxazole-3'-carbonyl)-L-ValΨ(COCH₂)-L-(4-F-Phe)-L-((S)-Pyrrol-Ala))-E-propanoate, (also referred to as AG7088), its analogs and of pharmaceutically acceptable salts thereof. The present invention also includes a novel group of key intermediate compounds to be used in the above process.

BACKGROUND OF THE INVENTION:

Picornaviruses are a family of tiny non-enveloped positive-stranded RNA-containing viruses that infect humans and other animals. These viruses include the human rhinoviruses, human polioviruses, human coxsackieviruses, human echoviruses, human and bovine enteroviruses, encephalomyocarditis viruses,

667280 8525709

115
112
2


meningitis viruses, foot and mouth viruses, hepatitis A virus, and others. The human rhinoviruses are a major cause of the common cold.

Proteolytic 3C enzymes are required for the natural maturation of the picornaviruses. Thus, inhibiting the activity of these proteolytic 3C enzymes should represent an important and useful approach for the treatment and cure of viral infections of this nature, including the common cold.

Some small-molecule inhibitors of the enzymatic activity of picornaviral 3C protease (i.e., antipicornaviral compounds) have been recently discovered. See, for example: U.S. Patent Application No. 08/850,398, filed May 2, 1997, by Webber et al.; U.S. Patent Application No. 08/991,282, filed December 16, 1997, by Dragovich et al.; and U.S. Patent Application No. 08/991,739, filed December 16, 1997, by Webber et al. These U.S. patent applications, the disclosures of which are incorporated herein by reference, describe certain antipicornaviral compounds and methods for their synthesis.

More recently, an especially potent group of antipicornaviral agents have been discovered as set forth in U.S. Patent Application No. 60/098,354, (the '354 application) filed August 28, 1998, by Dragovich et al., which is herein incorporated by reference. This application discloses, inter alias, a group of antipicornaviral agents of general formula I. A particularly promising compound, AG7088, falling within the scope of this group, exhibits excellent antiviral properties against a plethora of Rhinoviral serotypes and is currently in human clinical trials. The '354 application also discloses methods and intermediates useful for synthesizing these compounds. For example, General Method V therein discloses a general method for synthesizing the compounds of formula I involving subjecting a carboxylic acid of general formula

BB to an amide-forming reaction with an amine of general formula P to provide a final product CC, as shown below.



The '354 application further discloses methods for synthesizing the intermediates of general formulae BB and P, and teaches methods for carrying out the amide-forming reaction referred to above. Thus, the '354 application teaches suitable methods for synthesizing the compounds of general formula I from a carboxylic acid BB (within the scope of the compounds of general formula II referred to below) and the compounds of general formula P (the same as the compounds of general formula III referred to below.) Similarly, two recent publications by Dragovich et al. disclose antipicornavirus agents and suitable synthetic methods for their synthesis. See *Structure-Based Design, Synthesis, and Biological Evaluation of Irreversible Human Rhinovirus 3C Proteases Inhibitors*, 3. *StructureActivity Studies of Ketomethylene-Containing Peptidomimetics*, Dragovich et al., *Journal of Medicinal Chemistry*, ASAP, 1999; and *Structure-Based Design, Synthesis, and Biological Evaluation of*


Irreversible Human Rhinovirus 3C Proteases Inhibitors. 4. Incorporation of P₁ Lactam Moieties as L-Glutamine Replacements, Dragovich et al., Journal of Medicinal Chemistry, ASAP, 1999. These aforementioned articles are herein incorporated by reference in their entirety.

However, there is still a desire to discover improved, more efficient, processes and novel intermediates for use in the syntheses of the compounds of the group of antipicornaviral agents. In particular, there is a need for improved methods for synthesizing the compounds of general formulae II and III.

SUMMARY OF THE INVENTION:


The present invention relates to the discovery of a cost effective and efficient process for the preparation of the antipicornaviral agents of formula I, such as compound AG7088, as well as intermediates which are useful in that synthesis.

The antipicornaviral agents of formula I comprise:




wherein R₁ is H, F, an alkyl group, OH, SH, or an O-alkyl group;


R₂ and R₃ are each independently H;



where n is an integer from 0 to 5, A₁ is CH or N, A₂ and each A₃ are independently selected from C(R₄₁)(R₄₁), N(R₄₁), S, S(O), S(O)₂, and O, and A₄ is NH or NR₄₁, where each R₄₁ is independently H or lower alkyl, provided that no more than two heteroatoms occur consecutively in the above-depicted ring formed by A₁, A₂, (A₃)_n, A₄ and C=O, and at least one of R₂ and R₃ is



R₄ is



R₅ and R₆ are each independently H, F, an alkyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, or a heteroaryl group;

R₇ and R₈ are each independently H, an alkyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, a heteroaryl group, -OR₁₇, -SR₁₇, -NR₁₇R₁₈, -NR₁₉NR₁₇R₁₈, or -NR₁₇OR₁₈, where R₁₇, R₁₈, and R₁₉ are each independently H, an alkyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, a heteroaryl group, or an acyl group, provided that at least one of R₇ and R₈ is an alkyl group, an aryl group, a heteroaryl group, -OR₁₇, -SR₁₇, -NR₁₇R₁₈, -NR₁₉NR₁₇R₁₈, or -NR₁₇OR₁₈;
R₉ is a five-membered heterocycle having from one to three heteroatoms selected from O, N, and S; and

HA
716
7

Z and Z₁ are each independently H, F, an alkyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, a heteroaryl group, -C(O)R₂₁, -CO₂R₂₁, CN, -C(O)NR₂₁R₂₂, -C(O)NR₂₁OR₂₂, -C(S)R₂₁, -C(S)NR₂₁R₂₂, -NO₂, -SOR₂₁, -SO₂R₂₁, -SO₂NR₂₁R₂₂, -SO(NR₂₁)(OR₂₂), -SONR₂₁, -SO₃R₂₁, -PO(OR₂₁)₂, -PO(R₂₁)(R₂₂), -PO(NR₂₁R₂₂)(OR₂₃), -PO(NR₂₁R₂₂)(NR₂₃R₂₄), -C(O)NR₂₁NR₂₂R₂₃, or -C(S)NR₂₁NR₂₂R₂₃, where R₂₁, R₂₂, R₂₃, and R₂₄ are each independently H, an alkyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, a heteroaryl group, an acyl group, or a thioacyl group, or where any of two of R₂₁, R₂₂, R₂₃, and R₂₄, together with the atom(s) to which they are bonded, form a heterocycloalkyl group, provided that Z and Z₁ are not both H; or Z₁ and R₁, together with the atoms to which they are bonded, form a cycloalkyl or heterocycloalkyl group, where Z₁ and R₁ are as defined above except for moieties that cannot form the cycloalkyl or heterocycloalkyl group; or Z and Z₁, together with the atoms to which they are bonded, form a cycloalkyl or heterocycloalkyl group, where Z and Z₁ are as defined above except for moieties that cannot form the cycloalkyl or heterocycloalkyl group.

As discussed below, these antipicornaviral agents of formula I may be synthesized by subjecting a compound of general formula II together with a compound of general formula III to a suitable amide-forming reaction. The process of the present invention, not only reduces the number of steps required to synthesize the compounds of formula III, but more importantly, it also employs less expensive starting materials and reagents.

These objects, advantages and features of the present invention will be more fully understood and appreciated by reference to the written specification.

60150358 782499

120
117
7

DETAILED DESCRIPTION OF A PREFERRED EMBODIMENT OF THE
INVENTION:


As used in the present application, the following definitions apply:

In accordance with a convention used in the art,  is used in structural formulas herein to depict the bond that is the point of attachment of the moiety or substituent to the core or backbone structure.

Where chiral carbons are included in chemical structures, unless a particular orientation is depicted, both stereoisomeric forms are intended to be encompassed.


An "alkyl group" is intended to mean a straight- or branched chain monovalent radical of saturated and/or unsaturated carbon atoms and hydrogen atoms, such as methyl (Me), ethyl (Et), propyl, isopropyl, butyl (Bu), isobutyl, t-butyl (t-Bu), ethenyl, pentenyl, butenyl, propenyl, ethynyl, butynyl, propynyl, pentynyl, hexynyl, and the like, which may be unsubstituted (i.e., containing only carbon and hydrogen) or substituted by one or more suitable substituents as defined below (e.g., one or more halogens, such as F, Cl, Br, or I, with F and Cl being preferred). A "lower alkyl group" is intended to mean an alkyl group having from 1 to 4 carbon atoms in its chain.

A "cycloalkyl group" is intended to mean a non-aromatic monovalent monocyclic, bicyclic, or tricyclic radical containing 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, or 14 carbon ring atoms, each of which may be saturated or unsaturated, and which may be unsubstituted or substituted by one or more suitable substituents as defined below, and to which may be fused one or more heterocycloalkyl groups, aryl groups, or heteroaryl groups, which themselves may be unsubstituted or substituted by one or more substituents. Illustrative examples of cycloalkyl groups include the following moieties:




A "heterocycloalkyl group" is intended to mean a non-aromatic monovalent monocyclic, bicyclic, or tricyclic radical, which is saturated or unsaturated, containing 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, or 18 ring atoms, which includes 1, 2, 3, 4, or 5 heteroatoms selected nitrogen, oxygen, and sulfur, where the radical is unsubstituted or substituted by one or more suitable substituents as defined below, and to which may be fused one or more cycloalkyl groups, aryl groups, or heteroaryl groups, which themselves may be unsubstituted or substituted by one or more suitable substituents. Illustrative examples of heterocycloalkyl groups include the following moieties:

122
119
K




An "aryl group" is intended to mean an aromatic monovalent monocyclic, bicyclic, or tricyclic radical containing 6, 10, 14 or 18 carbon ring atoms, which may be unsubstituted or substituted by one or more suitable substituents as defined below, and to which may be fused one or more cycloalkyl groups, heterocycloalkyl groups, or heteroaryl groups, which themselves may be unsubstituted or substituted by one or more suitable substituents. Illustrative examples of aryl groups include the following moieties:



A "heteroaryl group" is intended to mean an aromatic monovalent monocyclic, bicyclic, or tricyclic radical containing 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, or 18 ring atoms, including 1, 2, 3, 4, or 5 heteroatoms selected from nitrogen, oxygen, and sulfur, which may be unsubstituted or substituted by one or

more suitable substituents as defined below, and to which may be fused one or more cycloalkyl groups, heterocycloalkyl groups, or aryl groups, which themselves may be unsubstituted or substituted by one or more suitable substituents. Illustrative examples of heteroaryl groups include the following moieties:



A "heterocycle" is intended to mean a heteroaryl or heterocycloalkyl group (each of which, as defined above, are optionally substituted).

124
127
7

An "acyl group" is intended to mean a $-C(O)-R$ radical, where R is a substituent as defined below.

A "thioacyl group" is intended to mean a $-C(S)-R$ radical, where R is a substituent as defined below.

A "sulfonyl group" is intended to mean a $-SO_2R$ radical, where R is a substituent as defined below.

A "hydroxy group" is intended to mean the radical $-OH$.

An "amino group" is intended to mean the radical $-NH_2$.

An "alkylamino group" is intended to mean the radical $-NHR_a$, where R_a is an alkyl group.

A "dialkylamino group" is intended to mean the radical $-NR_aR_b$, where R_a and R_b are each independently an alkyl group.

An "alkoxy group" is intended to mean the radical $-OR_a$, where R_a is an alkyl group. Exemplary alkoxy groups include methoxy, ethoxy, propoxy, and the like.

An "alkoxycarbonyl group" is intended to mean the radical $-C(O)OR_a$, where R_a is an alkyl group.

An "alkylsulfonyl group" is intended to mean the radical $-SO_2R_a$, where R_a is an alkyl group.

An "alkylaminocarbonyl group" is intended to mean the radical $-C(O)NHR_a$, where R_a is an alkyl group.

A "dialkylaminocarbonyl group" is intended to mean the radical $-C(O)NR_aR_b$, where R_a and R_b are each independently an alkyl group.

A "mercapto group" is intended to mean the radical $-SH$.

An "alkylthio group" is intended to mean the radical $-SR_a$, where R_a is an alkyl group.

125
122
X

A "carboxy group" is intended to mean the radical $-C(O)OH$.

A "carbamoyl group" is intended to mean the radical $-C(O)NH_2$.

An "aryloxy group" is intended to mean the radical $-OR_c$, where R_c is an aryl group.

A "heteroaryloxy group" is intended to mean the radical $-OR_d$, where R_d is a heteroaryl group.

An "arylthio group" is intended to mean the radical $-SR_c$, where R_c is an aryl group.

A "heteroarylthio group" is intended to mean the radical $-SR_d$, where R_d is a heteroaryl group.

A "leaving group" (Lv) is intended to mean any suitable group that will be displaced by a substitution reaction. One of ordinary skill in the art will know that any conjugate base of a strong acid can act as a leaving group. Illustrative examples of suitable leaving groups include, but are not limited to, $-F$, $-Cl$, $-Br$, alkyl chlorides, alkyl bromides, alkyl iodides, alkyl sulfonates, alkyl benzenesulfonates, alkyl p-toluenesulfonates, alkyl methanesulfonates, triflate, and any groups having a bisulfate, methyl sulfate, or sulfonate ion.

Typical protecting groups, reagents and solvents such as, but not limited to, those listed below in table 1 have the following abbreviations as used herein and in the claims. One skilled in the art would understand that the compounds listed within each group may be used interchangeably; for instance, a compound listed under "reagents and solvents" may be used as a protecting group, and so on. Further, one skilled in the art would know other possible protecting groups, reagents and solvents; these are intended to be within the scope of this invention.

126
123
X

Table 1

	Protecting Groups
Ada	Adamantane acetyl
Alloc	Allyloxycarbonyl
Allyl	Allyl ester
Boc	tert-butyloxycarbonyl
Bzl	Benzyl
Cbz	Benzyloxycarbonyl
Fmoc	Fluorenylmethyloxycarbonyl
OBzl	Benzyl ester
OEt	Ethyl ester
OMe	Methyl ester
Tos (Tosyl)	p-Toluenesulfonyl
Trt	Triphenylmethyl
	Reagents and Solvents
ACN	Acetonitrile
AcOH	Acetic acid
Ac.sub.2 O	Acetic acid anhydride
AdacOH	Adamantane acetic acid
AIBN	2,2-azobisisobutyronitrile
Alloc-Cl	Allyloxycarbonyl chloride
BHT	2,6-di-tert-butyl-4-methylphenol
Boc.sub.2 O	Di-tert butyl dicarbonate
CDI	1,1'-carbonyldiimidazole
DIEA	Diisopropylethylamine
DIPEA	N,N-diisopropylethylamine
DMA	Dimethylacetamide
DMF	N,N-dimethylformamide
DMSO	Dimethyl sulfoxide
EDTA	ethylenediaminetetraacetic acid
Et.sub.3 N	Triethylamine
EtOAc	Ethyl acetate
FDH	formate dehydrogenase
FmocOSu	9-fluorenylmethyloxy carbonyl N-hydroxysuccinimide ester
HATU	N-[(dimethylamino)-1H-1, 2, 3-triazol [4, 5-b] pyridylmethylene]-N-methylmethanaminium hexafluorophosphate N-oxide
HOBT	1-Hydroxybenzotriazole
HF	Hydrofluoric acid
LDH	lactate dehydrogenase
LiHMDS	Lithium bistrimethylsilylamide
MeOH	Methanol
Mes (Mesyl)	Methanesulfonyl
MTBE	t-butyl methyl ether
NAD	Nicotinamide adenine dinucleotide
NADH	Hydrogen-peroxide oxidoreductase
NaHMDS	Sodium bistrimethylsilylamide
NMP	1-methyl-2-pyrrolidinone

00150387 0821499

127
 124

nin.	Ninhydrin
i-PrOH	Iso-propanol
Pip	Piperidine
PPL	Lipase
pTSA	p-toluensulfonic acid monohydrate
Pyr	Pyridine
TEA	Triethylamine
TET	triethylenetetraamine
TFA	Trifluoroacetic acid
THF	Tetrahydrofuran
Triflate (Tf)	Trifluoromethanesulfonyl

The term "suitable organic moiety" is intended to mean any organic moiety recognizable, such as by routine testing, to those skilled in the art as not adversely affecting the inhibitory activity of the inventive compounds. Illustrative examples of suitable organic moieties include, but are not limited to, hydroxyl groups, alkyl groups, oxo groups, cycloalkyl groups, heterocycloalkyl groups, aryl groups, heteroaryl groups, acyl groups, sulfonyl groups, mercapto groups, alkylthio groups, alkoxy groups, carboxy groups, amino groups, alkylamino groups, dialkylamino groups, carbamoyl groups, arylthio groups, heteroarylthio groups, and the like.

The term "substituent" or "suitable substituent" is intended to mean any suitable substituent that may be recognized or selected, such as through routine testing, by those skilled in the art. Illustrative examples of suitable substituents include hydroxy groups, halogens, oxo groups, alkyl groups, acyl groups, sulfonyl groups, mercapto groups, alkylthio groups, alkyloxy groups, cycloalkyl groups, heterocycloalkyl groups, aryl groups, heteroaryl groups, carboxy groups, amino groups, alkylamino groups, dialkylamino groups, carbamoyl groups, aryloxy groups, heteroaryloxy groups, arylthio groups, heteroarylthio groups, and the like.

The term "optionally substituted" is intended to expressly indicate that the specified group is unsubstituted or substituted by one or more suitable substituents,

120
125
#

unless the optional substituents are expressly specified, in which case the term indicates that the group is unsubstituted or substituted with the specified substituents. As defined above, various groups may be unsubstituted or substituted (i.e., they are optionally substituted) unless indicated otherwise herein (e.g., by indicating that the specified group is unsubstituted).

A "prodrug" is intended to mean a compound that is converted under physiological conditions or by solvolysis or metabolically to a specified compound that is pharmaceutically active.

A "pharmaceutically active metabolite" is intended to mean a pharmacologically active product produced through metabolism in the body of a specified compound.

A "solvate" is intended to mean a pharmaceutically acceptable solvate form of a specified compound that retains the biological effectiveness of such compound. Examples of solvates include compounds of the invention in combination with water, isopropanol, ethanol, methanol, DMSO, ethyl acetate, acetic acid, or ethanolamine.

A "pharmaceutically acceptable salt" is intended to mean a salt that retains the biological effectiveness of the free acids and bases of the specified compound and that is not biologically or otherwise undesirable. Examples of pharmaceutically acceptable salts include sulfates, pyrosulfates, bisulfates, sulfites, bisulfites, phosphates, monohydrogenphosphates, dihydrogenphosphates, metaphosphates, pyrophosphates, chlorides, bromides, iodides, acetates, propionates, decanoates, caprylates, acrylates, formates, isobutyrate, caproates, heptanoates, propiolates, oxalates, malonates, succinates, suberates, sebacates, fumarates, maleates, butyne-1, 4-dioates, hexyne-1,6-dioates, benzoates, chlorobenzoates, methylbenzoates, dinitrobenzoates, hydroxybenzoates, methoxybenzoates, phthalates, sulfonates,

xylenesulfonates, phylacetates, phenylpropionates, phylbutyrates, citrates, lactates, γ -hydroxybutyrates, glycollates, tartrates, methane-sulfonates, propanesulfonates, naphthalene-1-sulfonates, naphthalene-2-sulfonates, and mandelates.

The present invention further provides synthetic methods that are comprised of one of the synthetic steps set forth in the present disclosure. A synthetic method is comprised of a synthetic step when the synthetic step is at least part of the final synthetic method. In such a fashion, the synthetic method can be only the synthetic step or have additional synthetic steps that may be associated with it. Such a synthetic method can have a few additional synthetic steps or can have numerous additional synthetic steps.

If the antipicornaviral agent of formula I formed from the process of the present invention is a base, a desired salt may be prepared by any suitable method known to the art, including treatment of the free base with an inorganic acid, such as hydrochloric acid; hydrobromic acid; sulfuric acid; nitric acid; phosphoric acid; and the like, or with an organic acid, such as acetic acid; maleic acid; succinic acid; mandelic acid; fumaric acid; malonic acid; pyruvic acid; oxalic acid; glycolic acid; salicylic acid; pyranosidyl acid, such as glucuronic acid or galacturonic acid; alpha-hydroxy acid, such as citric acid or tartaric acid; amino acid, such as aspartic acid or glutamic acid; aromatic acid, such as benzoic acid or cinnamic acid; sulfonic acid, such as p-toluenesulfonic acid or ethanesulfonic acid; or the like.

If the antipicornaviral agent of formula I formed from the process of the present invention is an acid, a desired salt may be prepared by any suitable method known to the art, including treatment of the free acid with an inorganic or organic base, such as an amine (primary, secondary, or tertiary); an alkali metal or alkaline earth metal hydroxide; or the like. Illustrative examples of suitable salts include

120
127
7

organic salts derived from amino acids such as glycine and arginine; ammonia; primary, secondary, and tertiary amines; and cyclic amines, such as piperidine, morpholine, and piperazine; as well as inorganic salts derived from sodium, calcium, potassium, magnesium, manganese, iron, copper, zinc, aluminum, and lithium.

In the case of compounds, salts, or solvates that are solids, it is understood by those skilled in the art that the compounds of formula I and the intermediates used in the process of the present invention, salts, and solvates thereof, may exist in different crystal forms, all of which are intended to be within the scope of the present invention and specified formulas.


5015035
064230

The antipicornaviral agents of formula I, and the intermediates used in the process of the present invention, may exist as single stereoisomers, racemates, and/or mixtures of enantiomers and/or diastereomers. All such single stereoisomers, racemates, and mixtures thereof are intended to be within the broad scope of the present invention. Preferably, however, the intermediate compounds used in the process of the present invention are used in optically pure form.

As generally understood by those skilled in the art, an optically pure compound is one that is enantiomerically pure. As used herein, the term "optically pure" is intended to mean a compound comprising at least a sufficient amount of a single enantiomer to yield a compound having the desired pharmacological activity. Preferably, "optically pure" is intended to mean a compound that comprises at least 90% of a single isomer (80% enantiomeric excess (hereinafter "e.e.")), more preferably at least 95% (90% e.e.), even more preferably at least 97.5% (95% e.e.), and most preferably at least 99% (98% e.e.) Preferably, the antipicornaviral agents of formula I formed from the process of the present invention are optically pure.


137
128
\$

The present invention relates to a process of preparing antipicornaviral agents
of formula I:



wherein R₁ is H, F, an alkyl group, OH, SH, or an O-alkyl group;


R₂ and R₃ are each independently H;



where n is an integer from 0 to 5, A₁ is CH or N, A₂ and each A₃ are independently selected from C(R₄₁)(R₄₁), N(R₄₁), S, S(O), S(O)₂, and O, and A₄ is NH or NR₄₁,


where each R₄₁ is independently H or lower alkyl, provided that no more than two heteroatoms occur consecutively in the above-depicted ring formed by A₁, A₂, (A₃)_n,

A₄ and C=O, and at least one of R₂ and R₃ is



132
129
77

R₄ is



R₅ and R₆ are each independently H, F, an alkyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, or a heteroaryl group;

R₇ and R₈ are each independently H, an alkyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, a heteroaryl group, -OR₁₇, -SR₁₇, -NR₁₇R₁₈, -NR₁₉NR₁₇R₁₈, or -NR₁₇OR₁₈, where R₁₇, R₁₈, and R₁₉ are each independently H, an alkyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, a heteroaryl group, or an acyl group, provided that at least one of R₇ and R₈ is an alkyl group, an aryl group, a heteroaryl group, -OR₁₇, -SR₁₇, -NR₁₇R₁₈, -NR₁₉NR₁₇R₁₈, or -NR₁₇OR₁₈; R₉ is a five-membered heterocycle having from one to three heteroatoms selected from O, N, and S; and

Z and Z₁ are each independently H, F, an alkyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, a heteroaryl group, -C(O)R₂₁, -CO₂R₂₁, CN, -C(O)NR₂₁R₂₂, -C(O)NR₂₁OR₂₂, -C(S)R₂₁, -C(S)NR₂₁R₂₂, -NO₂, -SOR₂₁, -SO₂R₂₁, -SO₂NR₂₁R₂₂, -SO(NR₂₁)(OR₂₂), -SONR₂₁, -SO₃R₂₁, -PO(OR₂₁)₂, -PO(R₂₁)(R₂₂), -PO(NR₂₁R₂₂)(OR₂₃), -PO(NR₂₁R₂₂)(NR₂₃R₂₄), -C(O)NR₂₁NR₂₂R₂₃, or -C(S)NR₂₁NR₂₂R₂₃, where R₂₁, R₂₂, R₂₃, and R₂₄ are each independently H, an alkyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, a heteroaryl group, an acyl group, or a thioacyl group, or where any of two of R₂₁, R₂₂, R₂₃, and


133
130
/

R₂₄, together with the atom(s) to which they are bonded, form a heterocycloalkyl group, provided that Z and Z₁ are not both H;

or Z₁ and R₁, together with the atoms to which they are bonded, form a cycloalkyl or heterocycloalkyl group, where Z₁ and R₁ are as defined above except for moieties that cannot form the cycloalkyl or heterocycloalkyl group;

or Z and Z₁, together with the atoms to which they are bonded, form a cycloalkyl or heterocycloalkyl group, where Z and Z₁ are as defined above except for moieties that cannot form the cycloalkyl or heterocycloalkyl group.


The present invention discloses that a compound of formula I may be prepared by subjecting a compound of formula II and a compound of formula III to an amide-forming reaction:



The amide-forming reaction may be achieved by any suitable method, reagents and reaction conditions. Preferably, any one of the methods disclosed in the '354 application is utilized. For example, a compound of formula II may be reacted with a compound of formula III in the presence of HATU, DIPEA, CH₃CN and H₂O to yield desired compound of formula I. Any suitable purification method may be used to further purify the compound of formula I.

More preferably, the compound of formula I is prepared by an amide-forming reaction comprising the steps of:

- (a) reacting the compound of formula II with a compound of formula IIIA in the presence of N-methylmorpholine to form a reaction mixture; and



- (b) adding a compound of formula Lv-X to the reaction mixture to form a compound of formula I, wherein X is any suitable halide.


Preferably, the method for preparing the compound of formula I utilizing the more preferable amide-forming reaction utilizes some or all of the reagents and reaction conditions disclosed below. Thus, preferably, the compound of formula II and the compound of formula IIIA in DMF are combined in any suitable container. The suitable container is preferably a single neck flask which is then covered with any suitable septum and covered with a temperature probe. Nitrogen gas is used to purge out the suitable container before N-methylmorpholine is added to the reaction mixture. More preferably, the N-methylmorpholine is added via a syringe in one single portion and the reaction mixture cooled to about between -5°C and 5°C . More preferably, the reaction mixture is cooled to about 0°C . A solution of the compound of formula Lv-X is then added to the reaction mixture. More preferably, the solution of the compound of formula Lv-X is a solution of the compound of formula Lv-X in DMF. Even more preferably, the compound of formula Lv-X is CDMT. The solution of the compound of formula Lv-X is added to the reaction mixture by any suitable method so as to maintain the reaction mixture at a constant temperature. For example, the solution of the compound of formula Lv-X may be added to the reaction mixture dropwise utilizing a syringe. Upon completion of the addition of the solution of the

13A
131
#


compound of formula Lv-X, the reaction mixture is allowed to warm to about room temperature. The progress of the reaction may be followed by monitoring the disappearance of the compound of formula II by thin layer chromatography (hereinafter "TLC"). When the reaction is at least substantially complete, the compound of formula I may be precipitated out of solution to form a slurry by slowly adding water to the reaction mixture. The compound of formula I may then be removed from the slurry by any suitable means known to one of ordinary skill in the art. For example, the compound of formula I may be removed from the slurry by filtration. Any suitable purification method known to one of ordinary skill in the art may be used to purify the compound of formula I. More preferably, the compound of formula I is purified by recrystallization.

The present invention also discloses two alternate processes for the synthesis of the compound of formula III and acid addition salts thereof. Of these two routes, the second process is currently preferred because it offers greater cost-effectiveness at a commercial scale.

The first of these two processes is for the preparation of a compound of formula IV and its acid addition salts from a compound of formula V.



(IV)



(V)


One of ordinary skill will recognize that the compounds of formula IV are a subgenus to those of formula III.

The compound of formula V may be prepared from commercially available N-Boc L glutamic acid γ - benzyl ester. Any suitable method may be used to prepare the compound of formula V. Preferably, the method disclosed in U.S. Patent Application No. 08/991,739 is used. U.S. Patent Application No. 08/991,739 is herein incorporated by reference in its entirety.


The process of the present invention comprises the steps of :

- (a) cyanomethylation of the compound of formula V using bis(trimethylsilyl)amide and bromoacetonitrile to yield a compound of formula VI;


137
134
135



(b) the reduction, cyclization, and deprotection of the compound of formula VI in that respective order to yield a compound of formula VII; and



(c) the oxidation and olefination of the compound of formula VII by reacting the compound with a SO_3 -pyridine complex to yield a reaction mixture and reacting the reaction mixture with a phosphorane of formula VIII.



130
135
X

According to the present invention, and as disclosed above, the preparation of the compound of formula V from N-Boc glutamic acid γ - benzyl ester may be carried out by any suitable method known in the art.

Further, the cyanomethylation of the compound of formula V may be carried out using any suitable method, reagents and reaction conditions. Preferably, the method disclosed below and the use of all or some of the reagents and reaction conditions are used. Thus, it is preferable, that the compound of formula V be added dropwise to a stirring solution of NaHMDS in THF at -70°C in a nitrogen atmosphere over a period of at least about 5 hours before being mixed with bromoacetonitrile.

50150351
032499

This cyanomethylation of the compound of formula V using bis(trimethylsilyl)amide and bromoacetonitrile affords the compound of formula VI along with its epimer in a 5:1 ratio. However, the compound may be purified by any suitable method. Preferably, the compound of formula VI is purified by filtration and chromatography, followed by titration. Under these preferred conditions, a 60% overall yield of the compound of formula VI is attainable having >99% diastereomeric purity.

The three step reduction, cyclization, and deprotection reaction of step (b) to convert the compound of formula VI to the compound of formula VII may be carried out using any suitable reagents and reaction conditions. Preferably, the method disclosed below, using all or some of the reagents and reaction conditions are used. Therefore, preferably, the compound of formula VI is reduced by adding a solution of cobalt (II) chloride hexahydrate to a solution of the compound of formula VI in tetrahydrofuran in methanol. The resulting solution is cooled to about 0°C before sodium borohydride is added in portions over a period of at least about 7 hours. Then, *p*-toluensulfonic acid monohydrate is added to the solution of crude material in

139
136
8

methanol and allowed to react for at least about 18 hours at an ambient temperature. After removal of the solvent, the residue is dissolved in ethyl acetate and washed. Any suitable washing agent may be used. More preferably, the washing agent is saturated sodium bicarbonate. The crude product is then charged with a solution of methanol in water. More preferably, a 2.5% methanol solution is used. The crude product may be removed from solution by any suitable method. For example, the crude product may be removed by filtration and the filtrate concentrated on a rotary evaporator. The product is then dissolved in ethyl acetate, dried, filtered and concentrated to the crude compound of formula VII. More preferably, the product is dried over MgSO_4 . The crude compound of formula VII may be further purified by any suitable purification process. More preferably, the crude compound of formula VII is purified through a titration process using 1:1 ethyl acetate and hexanes.

50150356
082499
1554230 35505105

An overall yield of at least about 95% pure compound of formula VII is attainable if the preferred three step reduction, cyclization, and deprotection reaction disclosed above is used.



Any suitable method, reagents and reaction conditions may be used in the subsequent oxidation and olefination employing a SO_3 -pyridine complex and the phosphorane of formula VIII to yield the compound of formula IV. Preferably, the method disclosed below and all or some of the reagents and reaction conditions are used. Accordingly, preferably, triethylamine is added to a solution of the compound of formula VIII and methylsulfoxide. The resulting solution is cooled to about 5°C , followed by the addition of a sulfur trioxide-pyridine complex. The reaction is stirred at about 5°C for at least about 15 minutes. After removing the source used to cool the solution to about 5°C , the reaction is stirred for at least about an additional 1 hour. (Carboethoxymethylenetriphenyl)-phosphorane is then added and the reaction mixture

stirred at ambient temperature for at least about 3 hours. Then, the reaction is quenched and extracted with ethyl acetate. More preferably, the reaction is quenched by the addition of saturated brine. The combined organic phases are then washed, dried, filtered and concentrated to afford crude compound of formula IV. More preferably, the combined organic phases are washed with saturated brine and dried over MgSO_4 .

The compound of formula IV may be purified by any suitable method. Preferably, chromatography purification and titration techniques are used. If the preferable purification technique is used, yields ranging from 55% to 60% are attainable.


The second process for preparing the compound of formula IV, and its acid addition salts, disclosed by the present invention comprises the steps of:

- (a) the dianionic alkylation of a compound of formula IX using bromoacetonitrile to yield a compound of formula X;




- (b) hydrogenation of the compound of formula X to yield an amine of formula XI;


At
138
5





(c) reacting the amine of formula XI with ET_3N to yield a lactam ester of formula XII;



(d) the reduction of the lactam ester of formula XII through a suitable reduction procedure to yield a compound of formula XIII;



(e) the oxidation and olefination of the compound of formula XIII to yield a compound of formula XIV by reacting it with a compound of formula XV; and



(f) converting the compound of formula XIV to the compound of formula IV.

Further, one of ordinary skill in the art will realize that the above disclosed method may be used to prepare the compound of formula XIV. Specifically, steps (a)-(e) disclose a process for preparing the compound of formula XIV.

The compound of formula IX may be prepared by any suitable method known in the art. For example, N-Boc L-(+)-glutamic acid dimethyl ester may be prepared from commercially available L-glutamic acid dimethyl ester hydrochloride or commercially available L-glutamic acid 5-methyl ester according to literature procedures. See for example, Shimamoto et al, J. Org. Chem. 1991, 56, 4167 and Duralski et al, Tetrahedron Lett. 1998, 30, 3585. These references are herein incorporated by reference in their entirety.

143
139
1

Preferably, the dianionic alkylation reaction is performed using the method and all or some of the reagents and reaction conditions disclosed below. Therefore, preferably, the compound of formula IX is first dissolved in THF to form a solution which is added dropwise to a stirring solution of LiHMDS at -78°C in an Argon atmosphere. The resulting mixture is then stirred at about -78°C for 2 hours before freshly distilled bromoacetonitrile is added dropwise over a period of 1 hour. The reaction mixture is stirred at about -78°C for additional 2 hours. The reaction is then quenched. More preferably, the reaction is quenched by adding 0.5 M HCl and H_2O . The resulting aqueous layer is separated and is extracted further with methyl *tert*-butyl ether. The combined organic extract is washed, dried and filtered. More preferably, the organic extract is washed with saturated NaHCO_3 and brine and dried over MgSO_4 . The solvent is evaporated under reduced pressure.

60150351 082499 061280 15205105

The compound of formula IX may be hydrogenated to the amine of formula XI by any suitable method known in the art. Preferably, the hydrogenation is performed in the presence of 5% Pd/C. More preferably, the hydrogenation reaction is performed in accordance with the method, using some or all of the reagents and reaction conditions disclosed below. According to this preferred hydrogenation method, the compound of formula IX is dissolved in HOAc and shaken with 5% Pd on C under H_2 gas, at 50 psi pressure, for 3 days. The mixture is then filtered over celite. The filtrate may then be evaporated under reduced pressure and the residue repeatedly evaporated from methyl *tert*-butyl ether.

The reaction of the amine of formula XI with Et_3N may be achieved using any suitable conditions. Preferably, the method and all or some of the reagents and reaction conditions disclosed below are used. Accordingly, preferably, the amine of formula XI is dissolved in 1:1 MeOH/THF, before Et_3N is added to the solution. The

144
1440
1440

resulting mixture is stirred at about 45°C for about 10 hours or until the starting material has disappeared. The presence of the starting material may be monitored by ¹H NMR. After stripping off the solvent, methyl *tert*-butyl ether is added. The precipitate is then filtered. 0.5 M HCl is added to the filtrate diluted with H₂O. After splitting the phases, the aqueous phase may be extracted with ethyl acetate. The combined organic phases are washed, dried, filtered and concentrated. More preferably, the combined organic phases are washed with brine and dried over MgSO₄. The phases may be concentrated on a rotovapor. Flash chromatography furnishes the lactam ester of formula XII.

60150351 0321409


Any suitable reduction method may be used to convert the lactam ester of formula XII to the compound of formula XIII. Preferably, LiBH₄ is used as the reducing agent. More preferably, the method, or any portion thereof, and any or all of the reagents and reaction conditions disclosed below are used. Thus, more preferably, LiBH₄ is added to a stirring solution of the lactam ester of formula XII in THF. The LiBH₄ is added in several portions at 0° C in an Argon atmosphere. The reaction mixture is stirred at 0° C for 10 minutes, before being allowed to warm to ambient temperature and stirred for an additional 2 hours. Then, the reaction is quenched. Even more preferably, the reaction is quenched by the dropwise addition of 0.5 M HCl while cooling using an ice bath. The solution is diluted with ethyl acetate and H₂O. After splitting the phases, the aqueous phase may be extracted with ethyl acetate. The combined organic phases are washed, dried, filtered and concentrated. Even more preferably, the combined organic phases are washed with brine and dried over MgSO₄. The phases may be concentrated on a rotovapor. Flash chromatography furnishes the compound of formula XII.

147

#55
#45
5


falling within the scope of formula I. Specifically, this example, as depicted in Scheme 1 below, illustrates the reaction of 1 with 2 to prepare the protease inhibitor AG7088.

Scheme 1




142
H16
X

The following examples disclose the preparation of compound 1 falling within the scope of formula IV. The first example, as depicted in Scheme 2 below, illustrates the use of the cyanomethylation route disclosed above. The second example, depicted in Scheme 3 below, illustrates the second more preferable cost effective route for preparing the same compound.



Scheme 3



Preparation of 4 (Scheme 2)

A solution of 3 (1.0 kg, 2.34 mol, 1.0 equiv.) in THF (8.0 L) was added dropwise to a stirring solution of NaHMDS in THF (1M in THF, 2.96 L, 1.28 equiv.) at -70°C in a nitrogen atmosphere over a period of 5 h. The resulting solution was stirred at -70°C for 0.5 h and freshly distilled bromoacetonitrile (320 mL, 2.0 equiv.) was then added dropwise over a period of 25 minutes. The reaction mixture was stirred at -70°C for additional 1 h until the disappearance of the starting material 3. The reaction was quenched by addition of saturated ammonium chloride solution (7.0 L), and extracted with methyl *tert*-butyl ether (24 L). The organic phase was washed with brine (3X6.0 L). The solvent was removed under reduce pressure to afford a

148
144
B

dark brown oil (1.5 kg). This crude product was dissolved in methylene chloride (8.0 L) and passed over a bed of silical gel (600 g) and activated carbon (250 g). After rinsing the cake with methylene chloride (4.0 L), the filtrate was concentrated on a rotary evaporator to afford a light brown oil (1,28 Kg), which was then dissolved in ethyl acetate (2.5 L). To the resulting solution, excess hexanes (14.5 L) were added under vigorous stirring and a white solid precipitated out in 30 minutes. The slurry was cooled with an ice-water bath and stirred for 4.5 h, followed by filtration to afford 4 as a light brown solid (662 g, 60%): ^1H NMR (CDCl_3) δ 1.46 (s, 3 H), 1.49 (s, 9 H), 1.59 (s, 3 H), 1.75-1.95 (m, 1 H), 2.15-2.31 (m, 1 H), 2.55-3.15 (m, 3 H), 3.36 (d, J = 10.8 Hz, 1 H); 3.62-4.10 (m, 3 H), 4.13-4.32 (m, 3 H), 4.70 (m, 1 H), 7.15-7.42 (m, 5 H).

Preparation of 6 (Scheme 3)

Compound 6 was prepared from L-glutamic acid dimethyl ester hydrochloride (commercially available from Lancaster) or L-glutamic acid 5-methyl ester (commercially available from Aldrich) according to literature procedures.

Preparation of 7 (Scheme 3)

A solution of N-Boc L-(+)-glutamic acid dimethyl ester (6, 10 g, 36.3 mmol, 1 equiv.) in THF (100 mL) was added dropwise to a stirring solution of LiHMDS (77 mL, 1M in THF, 77.0 mmol, 2.1 equiv.) at -78°C in an Ar atmosphere. The resulting dark mixture was stirred at -78°C for 2 h, and then freshly distilled bromoacetonitrile (13.1g, 109.0 mmol, 3 equiv.) was added dropwise over a period of 1 h. The reaction mixture was stirred at -78°C for additional 2 h and the disappearance of the starting material (6) was confirmed by TLC analysis. The reaction was quenched by addition of HCl (120mL, 0.5 M) and H_2O (200 mL). The layers were separated, and the aqueous layer was further extracted with methyl tert-butyl ether (3 x 200 mL). The

149
145
/

combined organic extract was washed with saturated NaHCO_3 (2 x 250 mL), brine (2 x 250 mL), dried over MgSO_4 and filtered. The solvent was evaporated under reduce pressure to give a brown oil (15.2 g). Flash chromatography over silica gel (3 : 1 hexanes/ethyl acetate) afforded a colorless oil (7, 6.67 g, 10.8 mmol, 58%): ^1H NMR (CDCl_3) δ 1.46 (s, 9 H), 2.12-2.24 (m, 2 H), 2.77-2.82 (m, 2 H), 2.85-2.91 (m, 1 H), 3.78 (s, 3 H), 3.79 (s, 3 H), 4.32-4.49 (m, 1 H), 5.13 (d, $J = 6.0$ Hz, 1 H); ^{13}C NMR (CDCl_3) δ 19.4, 28.6, 34.3, 38.6, 49.8, 53.1, 80.9, 117.5, 155.9, 172.4, 172.8; HRMS m/z 314.1481 (calculated for $\text{C}_{12}\text{H}_{22}\text{N}_2\text{O}_4$, 314.1486).

Preparation of 8 (Scheme 3)

Compound 7 (4.60 g, 14.6 mmol) was dissolved in HOAc (120 mL) and shaken with 5% Pd on C (20 g) under H_2 gas (50 psi) for 3 days. The mixture was filtered over Celite. The filtrate was evaporated under reduced pressure and the residue was repeatedly evaporated from methyl *tert*-butyl ether to yield a light pink solid (8, 8.32 g), which was used directly in the next step. ^1H NMR (CD_3OD) δ 1.47 (s, 9 H), 1.85-2.10 (m, 4 H), 2.60-2.62 (m, 1 H), 2.92-2.96 (m, 2 H), 3.74 (s, 3 H), 3.77 (s, 3 H), 4.22-4.26 (m, 1 H); Note: Experiments have demonstrated that less 5% Pd on C can drive the reaction to completion, i.e., 1 g of 5% Pd on C was efficient for the reduction of 2 g of 7.

Preparation of 9 (Scheme 3)

Crude 8 was dissolved in 1:1 MeOH/THF (40 mL) and Et_3N (7 mL) was added to the solution. The resulting mixture was stirred at 45°C for 10 h until the disappearance of the starting material monitored by ^1H NMR. After stripping off the solvent on a rotovapor, methyl *tert*-butyl ether (200 mL) was added and a white solid precipitated out. The solid precipitate was removed by filtration. The filtrate was diluted with 200 mL of H_2O followed by addition of 0.5 M HCl (5 mL). The phases

150
146
7

were split, and the aqueous phase was extracted with ethyl acetate (4 x 200 mL). The combined organic phases were washed with brine (2x700 mL), dried over MgSO_4 , filtered and concentrated on a rotovapor to give a light brown oil. Flash chromatography furnished a white solid (9, 2.5 g, 8.74 mmol, 60%): ^1H NMR (CDCl_3) δ 1.37 (s, 9 H), 1.75-1.80 (m, 2 H), 2.04-2.09 (m, 1 H), 2.39-2.42 (m, 2 H), 3.25-3.29 (m, 2 H), 3.67 (s, 3 H), 4.23-4.26 (m, 1 H), 5.47 (d, $J = 8.0$ Hz, 1 H), 6.29 (s, 1 H); ^{13}C NMR (CDCl_3) δ 28.5, 28.6, 34.5, 38.5, 40.7, 52.7, 52.8, 80.3, 156.1, 173.3, 180.0; HRMS m/z 286.1564 (calculated for $\text{C}_{13}\text{H}_{22}\text{N}_2\text{O}_5$, 286.1587).

Preparation of 5 from 4 (Scheme 2)

To a solution of 4 (400 g, 0.85 mol, 1 equiv.) in tetrahydrofuran (3.0 L) was added a solution of cobalt (II) chloride hexahydrate (200 g, 0.85 mol, 1 equiv.) in methanol (3.0 L). The resulting solution was cooled to 0°C and sodium borohydride (130 g, 3.51 mol, 4.4 equiv.) was added in portions over a period of 7 h. The reaction mixture was allowed to warm to ambient temperature and stirred for 20 h while being monitored by TLC for the disappearance of the starting material (4). The reaction was cooled to 0°C and quenched by addition of 1.0 M HCl (14 L) and ethyl acetate (12 L). The phases were separated and the aqueous phase was charged with 2.0 kg of sodium chloride and 4.0 L of ethyl acetate. The phases were separated, and the organic phases were combined, washed with brine (1X3.0 L), concentrated on a rotary evaporator to afford a crude material (440 g), which was used directly in the following hydrolysis reaction. To a solution of the crude material (440 g, 1 equiv.) in methanol (800 mL) was added *p*-toluensulfonic acid monohydrate (4.0 g, 0.015 equiv.). The reaction was stirred at ambient temperature overnight. The solvent was removed on a rotary evaporator and the residue was dissolved in ethyl acetate (2.0 L), washed with saturated sodium bicarbonate (2X100 mL). The combined aqueous

151
147
X

phases were extracted with ethyl acetate (2X200 mL). All the organic phases were combined, concentrated on a rotary evaporator to afford 275 g of the crude product, which was charged with a solution of 2.5% methanol (20 mL) in water (780 mL) and stirred at ambient temperature overnight. The granular solid (chiral auxiliary) was removed by filtration and the filtrate was concentrated on a rotary evaporator. The residue was dissolved in ethyl acetate (1.5L), dried over MgSO_4 , filtered and concentrated to afford a viscous oil. The oil was further purified through a titration process using 1: 1 ethyl acetate (1 L) and hexanes (1 L) to afford 5 as a white solid (104 g, 47% overall yield from 4).

Preparation of 5 from 9 (Scheme 3)

To a stirring solution of 9 (1.75 g, 6.10 mmol) in THF (40 mL) was added LiBH_4 (270 mg, 12.2 mmol, 2 equiv.) in several portions at 0°C in an Argon atmosphere. The reaction mixture was stirred at 0°C for 10 minutes, then allowed to warm to ambient temperature and stirred for additional 2 h. The reaction was quenched by the dropwise addition of 0.5 M HCl (24 mL) with cooling in an ice bath (Note: formation of gases was observed). The solution was diluted with ethyl acetate (100 mL) and H_2O (50 mL). The phases were split, and the aqueous layer was extracted with ethyl acetate (6 x 150 mL). The combined organic phases were dried over MgSO_4 , filtered and concentrated on rotovapor to give a light brown oil. Flash chromatography afforded a white solid (5, 1.308 g, 5.06 mmol, 83%): ^1H NMR (CDCl_3) δ 1.46 (s, 9 H), 1.61-1.67 (m, 1 H), 1.82-1.91 (m, 1 H), 1.94-2.00 (m, 1 H), 2.43-2.48 (m, 1 H), 2.49-2.55 (m, 1 H), 3.32-3.34 (m, 3 H), 3.58-3.66 (m, 2 H), 3.68-3.79 (m, 2 H), 5.47 (d, $J = 7.0$ Hz, 1 H), 6.24 (s, 1 H); ^{13}C NMR (CDCl_3) δ 28.8, 32.9, 38.4, 40.8, 51.5, 66.3, 79.8, 157.0, 181.3; HRMS m/z 258.1652 (calculated for $\text{C}_{13}\text{H}_{22}\text{N}_2\text{O}_5$, 258.1650).

152
148
P

Preparation of 1 from 5

Procedure A (Scheme 2)

To a solution of 5 (50.0 g, 0.184 mol, 1 equiv.) in methanesulfoxide (500 mL) was added triethylamine (116 mL). The resulting solution was cooled to 5°C with an ice bath, followed by addition of sulfur trioxide-pyridine complex (132 g). The reaction was stirred at that temperature for 15 min. The cold bath was removed and the reaction was stirred for additional 1 h. (Carboethoxymethylenetriphenyl)-phosphorane (112 g) was added in one lot and the reaction was stirred at ambient temperature for 3 h. The reaction was quenched by addition of saturated brine (3.0 L), extracted with ethyl acetate (3X1.5 L). The combined organic phases were washed with saturated brine (3X1.5 L), dried over MgSO_4 , filtered and concentrated to afford a dark red oil. The oil was purified through a chromatography, followed by a titration process using ethyl acetate (60 mL) and excess of hexanes (240 mL). 1 was obtained as a white solid (36.0 g, 60%).

Procedure B (Scheme 3)

To a solution of 5 (1.0 g, 3.87 mmol, 1 equiv.) in CH_2Cl_2 (80 mL) was added benzoic acid (1.89 g, 15.5 mmol, 4 equiv.), (carboethoxymethylenetriphenyl)phosphorane (5.39g, 15.5 mmol, 4 equiv.) and DMSO (4.8 mL). Dess-Martin periodinane (4.1 g, 9.17 mmol, 2.5 equiv.) was added in several portions to the solution, and the reaction mixture was then stirred for 5 h at ambient temperature until the disappearance of the starting material 5. Saturated NaHCO_3 solution was added, and the mixture was stirred for 30 minutes. A white solid precipitated out, which was then filtered off. The organic phase of the filtrate was separated, washed with brine (250 mL), and concentrated on rotovapor to give a brown oil, which was purified by flash chromatography to produce a light brown

155
149
7

foam (0.956 g). The foam was dissolved in ethyl acetate (3 mL). Excess hexanes (12 mL) was added gradually to the stirring solution and a white solid precipitated out. The solid was filtered and dried in vacuum oven overnight to afford **1** (0.69g, 2.11 mmol, 55%). Chiral HPLC: 97% pure, 98% *de* and 100% *E* isomer; ¹H NMR (CDCl₃) δ 1.22 (t, *J* = 7.2 Hz, 3 H), 1.38 (s, 9 H), 1.53-1.58 (m, 1 H), 1.66-1.84 (m, 1H), 1.85-2.00 (m, 1 H), 2.30-2.50 (m, 2 H), 3.20-3.37 (m, 2H), 4.13 (q, *J* = 7.2 Hz, 2 H), 4.20-4.35 (m, 1 H), 5.13 (d, *J* = 7.5 Hz, 1 H), 5.68 (s, 1 H), 5.90 (dd, *J* = 1.8, 15.6 Hz, 1 H), 6.80 (dd, *J* = 5.1, 15.6 Hz, 1 H); HRMS *m/z* 326.1846 (calculated for C₁₆H₂₆N₂O₆, 326.1840).

Preparation of AG7088 from **1** and **2** (Scheme 1).

751 mg of compound **1** was dissolved in DCM (10 mL/g of **1**) in a single neck round bottom flask and cover with a septum. The flask was then purged with nitrogen followed by the addition of 1.4 mL TFA via syringe while the solution was being stirred. The progress of the reaction was monitored by TLC using 5% MeOH in DCM until after about 4 hours the starting material disappeared. The solvent and excess TFA were removed under vacuum at pressure of <50 mTorr @ 45°C. The product, compound **1A**, was used immediately in the step set forth below.

Compounds **1A** and **2** were dissolved in DMF (7 mL/g of **2**) in a single neck flask covered with a septum and fitted with a temperature probe. The flask was purged with nitrogen. The resulting solution was divided into two portions. In a first portion was added 1.6 mL *n*-methyilmorpholine via syringe and cooled to 0°C ± 5°C. In a second portion of the solution 281 mg CDMT was dissolved. This CDMT solution was then added dropwise via syringe to the first portion of the solution, maintaining the reaction temperature of 0°C ± 5°C. The resulting reaction mixture was then allowed to warm to room temperature. The reaction was monitored for

150
154
~~154~~

about 1 hour by TLC (7:3:1 hexanes:EtOAc:IPA) until the compound 2 disappeared. Once the reaction was complete the product AG7088 was precipitated out of solution by the slow addition of water to reaction mixture. The resulting slurry was filtered to obtain a yield of >85% white granular crystals of compound AG7088 having a purity of >97%. The product may then be recrystallized by dissolving it in hot MeOH:EtOAc 1:1 followed by slow addition of hexanes (2 vols.)



It is to be understood that the foregoing description is exemplary and explanatory in nature, and is intended to illustrate the invention and its preferred embodiments. Through routine experimentation, the artisan will recognize apparent modifications and variations that may be made without departing from the spirit of the invention. Thus, the invention is intended to be defined not by the above description, but by the following claims and their equivalents.

157
155
X


WHAT IS CLAIMED IS:

1. A process useful in synthesizing antipicornaviral compounds, comprising:

- (a) performing cyanomethylation of a compound of formula V using bis(trimethylsilyl)amide and bromoacetonitrile to yield a compound of formula VI;




- (b) performing reduction, then cyclization, and then deprotection of the compound of formula VI to yield a compound of formula VII; and



- (c) performing oxidation and olefination of the compound of formula VII by reacting the compound of formula VII with a SO₃-pyridine complex to

yield a reaction mixture and reacting the reaction mixture with a compound for formula VIII to form a compound of formula IV:



wherein R_1 is H, F, an alkyl group, OH, SH, or an O-alkyl group;


where each R_{41} is independently H or lower alkyl; and

X is any suitable protecting group for nitrogen.

2. The process of claim 1, wherein the compound of formula V is prepared from N-Boc L glutamic acid γ -benzyl ester.
3. The process of claim 1, wherein X is a Boc group.
4. The process of claim 1, wherein R_{41} is H.
5. The process of claim 1, wherein Z_1 is H.
6. The process of claim 1, wherein Z is $-\text{COOEt}$.
7. A process useful in synthesizing antipicornaviral compounds according to claim 1, further comprising the steps of:


(d) deprotecting the compound of formula IV to yield a compound of formula

IVA:







(e) subjecting a compound of formula II and the compound of formula IVA to an amide-forming reaction to yield a compound of formula IA:



wherein R_2 and R_3 are each independently H;




where n is an integer from 0 to 5, A_1 is CH or N, A_2 and each A_3 are independently selected from $C(R_{41})(R_{41})$, $N(R_{41})$, S, $S(O)$, $S(O)_2$, and O, and A_4 is NH or NR_{41} , where each R_{41} is independently H or lower alkyl, provided that no more than two heteroatoms occur consecutively in the above-depicted ring formed by A_1 , A_2 , $(A_3)_n$, A_4 and $C=O$, and at least one of R_2 and R_3 is



R_4 is

A



R_5 and R_6 are each independently H, F, an alkyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, or a heteroaryl group;

R_7 and R_8 are each independently H, an alkyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, a heteroaryl group, $-OR_{17}$, $-SR_{17}$, $-NR_{17}R_{18}$, $-NR_{19}NR_{17}R_{18}$, or $-NR_{17}OR_{18}$, where R_{17} , R_{18} , and R_{19} are each independently H, an alkyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, a heteroaryl group, or an acyl group, provided that at least one of R_7 and R_8 is an alkyl group, an aryl group, a heteroaryl group, $-OR_{17}$, $-SR_{17}$, $-NR_{17}R_{18}$, $-NR_{19}NR_{17}R_{18}$, or $-NR_{17}OR_{18}$; R_9 is a five-membered heterocycle having from one to three heteroatoms selected from O, N, and S; and

Z and Z_1 are each independently H, F, an alkyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, a heteroaryl group, $-C(O)R_{21}$, $-CO_2R_{21}$, CN, $-C(O)NR_{21}R_{22}$, $-C(O)NR_{21}OR_{22}$, $-C(S)R_{21}$, $-C(S)NR_{21}R_{22}$, $-NO_2$, $-SOR_{21}$, $-SO_2R_{21}$, $-SO_2NR_{21}R_{22}$, $-SO(NR_{21})(OR_{22})$, $-SONR_{21}$, $-SO_3R_{21}$, $-PO(OR_{21})_2$, $-PO(R_{21})(R_{22})$, $-PO(NR_{21}R_{22})(OR_{23})$, $-PO(NR_{21}R_{22})(NR_{23}R_{24})$, $-C(O)NR_{21}NR_{22}R_{23}$, or $-C(S)NR_{21}NR_{22}R_{23}$, where R_{21} , R_{22} , R_{23} , and R_{24} are each independently H, an alkyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, a heteroaryl group, an acyl group, or a thioacyl group, or where any of two of R_{21} , R_{22} , R_{23} , and R_{24} , together with the atom(s) to which they are bonded, form a heterocycloalkyl group, provided that Z and Z_1 are not both H;


159
155

or Z_1 and R_1 , together with the atoms to which they are bonded, form a cycloalkyl or heterocycloalkyl group, where Z_1 and R_1 are as defined above except for moieties that cannot form the cycloalkyl or heterocycloalkyl group;


or Z and Z_1 , together with the atoms to which they are bonded, form a cycloalkyl or heterocycloalkyl group, where Z and Z_1 are as defined above except for moieties that cannot form the cycloalkyl or heterocycloalkyl group.

8. The process of claim 7, wherein X is a Boc group.


9. The process of claim 7, wherein compound IV is



10. The process of claim 7, wherein the compound of formula II is




11. The process of claim 7, wherein the compound of formula IVA is




12. The process according to claim 7, wherein the compound of formula IA is

160
156




13. A process useful in synthesizing antipicornaviral compounds, comprising:


- (a) performing dianionic alkylation of a compound of formula IX using bromoacetonitrile to prepare a compound of formula X;



- (b) performing hydrogenation of the compound of formula X to yield an amine of formula XI;




- (c) reacting the compound of formula XI with ET₃N to yield a lactam ester of formula XII;




157

(d) performing reduction of the lactam ester of formula XII to yield a compound of formula XIII:



(e) performing oxidation and olefination of the compound of formula XIII to yield a compound of formula XIV by reacting it with a compound of formula XV:



wherein each R_{41} is independently H or lower alkyl;

Z and Z_1 are each independently H, F, an alkyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, a heteroaryl group, $-C(O)R_{21}$, $-CO_2R_{21}$, CN, $-C(O)NR_{21}R_{22}$, $-C(O)NR_{21}OR_{22}$, $-C(S)R_{21}$, $-C(S)NR_{21}R_{22}$, $-NO_2$, $-SOR_{21}$, $-SO_2R_{21}$, $-SO_2NR_{21}R_{22}$, $-SO(NR_{21})(OR_{22})$, $-SONR_{21}$, $-SO_3R_{21}$, $-PO(OR_{21})_2$, $-PO(R_{21})(R_{22})$, $-PO(NR_{21}R_{22})(OR_{23})$, $-PO(NR_{21}R_{22})(NR_{23}R_{24})$, $-C(O)NR_{21}NR_{22}R_{23}$, or $-C(S)NR_{21}NR_{22}R_{23}$, where R_{21} , R_{22} , R_{23} , and R_{24} are each independently H, an alkyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, a heteroaryl group, an acyl group, or a thioacyl group, or where any of two of R_{21} , R_{22} , R_{23} , and

158 ~~162~~

R₂₄, together with the atom(s) to which they are bonded, form a heterocycloalkyl


group, provided that Z and Z₁ are not both H;

or Z and Z₁, together with the atoms to which they are bonded, form a cycloalkyl or heterocycloalkyl group, where Z and Z₁ are as defined above except for moieties that cannot form the cycloalkyl or heterocycloalkyl group; and

X is any suitable protecting group for nitrogen.

14. The process useful in synthesizing antipicornaviral compounds according to claim 13, further comprising:


preparing a compound of formula IV by converting the compound of formula XIV to yield the compound of formula IV:



wherein R₁ is H, F, an alkyl group, OH, SH, or an O-alkyl group.

15. The process useful in synthesizing antipicornaviral compounds according to claim 14, further comprising:


Step A: deprotecting the compound of formula IV to yield a compound of formula IVA:




159
163

7


Step B: subjecting a compound of formula II and the compound of formula IVA to an amide-forming reaction to yield a compound of formula IA:




wherein R_2 and R_3 are each independently H;



where n is an integer from 0 to 5, A_1 is CH or N, A_2 and each A_3 are independently selected from $C(R_{41})(R_{42})$, $N(R_{41})$, S, $S(O)$, $S(O)_2$, and O, and A_4 is NH or NR_{41} , where each R_{41} is independently H or lower alkyl, provided that no more than two heteroatoms occur consecutively in the above-depicted ring formed by A_1 , A_2 , $(A_3)_n$, A_4 and $C=O$, and at least one of R_2 and R_3 is



R_4 is



R_5 and R_6 are each independently H, F, an alkyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, or a heteroaryl group;

R_7 and R_8 are each independently H, an alkyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, a heteroaryl group, $-OR_{17}$, $-SR_{17}$, $-NR_{17}R_{18}$, $-NR_{19}NR_{17}R_{18}$, or $-NR_{17}OR_{18}$, where R_{17} , R_{18} , and R_{19} are each independently H, an alkyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, a heteroaryl group, or an acyl group, provided that at least one of R_7 and R_8 is an alkyl group, an aryl group, a heteroaryl group, $-OR_{17}$, $-SR_{17}$, $-NR_{17}R_{18}$, $-NR_{19}NR_{17}R_{18}$, or $-NR_{17}OR_{18}$; R_9 is a five-membered heterocycle having from one to three heteroatoms selected from O, N, and S;


Z and Z_1 are each independently H, F, an alkyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, a heteroaryl group, $-C(O)R_{21}$, $-CO_2R_{21}$, CN, $-C(O)NR_{21}R_{22}$, $-C(O)NR_{21}OR_{22}$, $-C(S)R_{21}$, $-C(S)NR_{21}R_{22}$, $-NO_2$, $-SOR_{21}$, $-SO_2R_{21}$, $-SO_2NR_{21}R_{22}$, $-SO(NR_{21})(OR_{22})$, $-SONR_{21}$, $-SO_3R_{21}$, $-PO(OR_{21})_2$, $-PO(R_{21})(R_{22})$, $-PO(NR_{21}R_{22})(OR_{23})$, $-PO(NR_{21}R_{22})(NR_{23}R_{24})$, $-C(O)NR_{21}NR_{22}R_{23}$, or $-C(S)NR_{21}NR_{22}R_{23}$, where R_{21} , R_{22} , R_{23} , and R_{24} are each independently H, an alkyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, a heteroaryl group, an acyl group, or a thioacyl group, or where any of two of R_{21} , R_{22} , R_{23} , and R_{24} , together with the atom(s) to which they are bonded, form a heterocycloalkyl group, provided that Z and Z_1 are not both H;

or Z_1 and R_1 , together with the atoms to which they are bonded, form a cycloalkyl or heterocycloalkyl group, where Z_1 and R_1 are as defined above except for moieties that cannot form the cycloalkyl or heterocycloalkyl group;

165
161


or Z and Z₁, together with the atoms to which they are bonded, form a cycloalkyl or heterocycloalkyl group, where Z and Z₁ are as defined above except for moieties that cannot form the cycloalkyl or heterocycloalkyl group.

15. The process of claim 13, wherein X is a Boc group.
16. The process of claim 13, wherein R₄₁ is H.
17. The process of claim 13, wherein Z₁ is H.
18. The process of claim 13, wherein Z is -COOEt.
19. The process of claim 14, wherein R₁ is H.
20. A process useful for the synthesis of a compound of formula IA', and acid addition salts thereof:



comprising the steps of:


Step A: preparing a compound of formula IV':





comprising:

166
162
17

(a) performing cyanomethylation of a compound of formula V' using bis(trimethylsilyl)amide and bromoacetonitrile to yield a compound of formula VI;




(b) performing reduction, then cyclization, and then deprotection of the compound of formula VI to yield a compound of formula VII; and




(c) performing oxidation and olefination of the compound of formula VII by reacting the compound with a SO_3 -pyridine complex before the resulting reaction mixture is reacted with $\text{Ph}_3\text{P}=\text{CHCO}_2\text{Et}$;

167
163
77



Step B: deprotecting the compound of formula IV to yield a compound of formula IVA':



Step C: subjecting a compound of formula II' and the compound of formula IVA' to an amide-forming reaction;




21. The process of claim 20, wherein the compound of formula V is prepared from N-Boc L glutamic acid γ -benzyl ester.
22. A process useful in synthesizing anticomaviral compounds, comprising:
 - (a) performing dianionic alkylation of a compound of formula IX' using bromoacetonitrile to prepare a compound of formula X';




168
164
8


(b) performing hydrogenation of the compound of formula X' to yield an amine of formula XI';



(c) reacting the compound of formula XI' with Et_3N to yield a lactam ester of formula XII';




(d) performing reduction of the lactam ester of formula XII' to yield a compound of formula XIII':



(e) performing oxidation and olefination of the compound of formula XIII' to yield a compound of formula XIV' by reacting it with $\text{Ph}_3\text{P}=\text{CHCO}_2\text{Et}$;


169
165
7



23. The process useful in synthesizing antipicornaviral compounds according to claim

22, further comprising:


converting the compound of formula XIV' to the compound of formula IV';



24. The process useful in synthesizing antipicornaviral compounds according to claim

23, further comprising:

Step A: deprotecting the compound of formula IV' to yield a compound of formula IVA':




170
166
X

; and

Step C: subjecting a compound of formula II' and the compound of formula

IVA' to an amide-forming reaction;



654230-7E05T09

177
167
Z

ABSTRACT:

Efficient synthetic routes for the preparation of rhinovirus protease inhibitors of formula I, as well as key intermediates useful in those synthetic routes. These compounds of formula I, as well as pharmaceutical compositions that contain these compounds, are suitable for treating patients or hosts infected with one or more picornaviruses.

